CSBio CSBio

X
[{"orgOrder":0,"company":"Marinomed Biotech","sponsor":"Luoxin Pharmaceutical","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"$2.0 million","newsHeadline":"Luoxin Pharmaceutical Signs Licensing Agreement With Austria-based Marinomed Biotech AG for Budesolv\u00ae Budesonide Nasal Spray","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase III","country":"AUSTRIA","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Marinomed Biotech"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreement, Shandong Luoxin will gain the exclusive rights for the development, manufacture, and commercialization of Budesolv® (Budesonide Nasal spray) in China (including Chinese mainland, Hong Kong and Macao SAR, Taiwan region).

            Lead Product(s): Budesonide

            Therapeutic Area: Immunology Product Name: Budesolv

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Luoxin Pharmaceutical

            Deal Size: $22.0 million Upfront Cash: $2.0 million

            Deal Type: Licensing Agreement October 19, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY